These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 9664143)

  • 1. Effects of oncostatin M and tamoxifen on human melanoma cells.
    Gibbs P; Chen Q; Robinson WA
    Melanoma Res; 1998 Jun; 8(3):221-6. PubMed ID: 9664143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-stage lesions.
    Lu C; Rak JW; Kobayashi H; Kerbel RS
    Cancer Res; 1993 Jun; 53(12):2708-11. PubMed ID: 8504408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines.
    McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
    Br J Cancer; 1994 Sep; 70(3):449-52. PubMed ID: 8080729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the Jak-Stat- and MAPK-pathways by oncostatin M is not sufficient to cause growth inhibition of human glioma cells.
    Halfter H; Postert C; Friedrich M; Ringelstein EB; Stögbauer F
    Brain Res Mol Brain Res; 2000 Sep; 80(2):198-206. PubMed ID: 11038252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of tamoxifen on the secretion of transforming growth factor-beta2 (TGF-beta2) in glioblastomas: in vitro and in vivo findings.
    Puchner MJ; Köppen JA; Zapf S; Knabbe C; Westphal M
    Anticancer Res; 2002; 22(1A):45-51. PubMed ID: 12017331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.
    McClay EF; Jones JA; Winski PJ; Albright KD; Christen RD; Howell SB
    Cancer Res; 1996 Sep; 56(17):3993-7. PubMed ID: 8752169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncostatin M is a differentiation factor for myeloid leukemia cells.
    Bruce AG; Hoggatt IH; Rose TM
    J Immunol; 1992 Aug; 149(4):1271-5. PubMed ID: 1380037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formation of autocrine loops in human cerebral meningioma tissue by leukemia inhibitor factor, interleukin-6, and oncostatin M: inhibition of meningioma cell growth in vitro by recombinant oncostatin M.
    Schrell UM; Koch HU; Marschalek R; Schrauzer T; Anders M; Adams E; Fahlbusch R
    J Neurosurg; 1998 Mar; 88(3):541-8. PubMed ID: 9488310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells.
    Liu J; Hadjokas N; Mosley B; Estrov Z; Spence MJ; Vestal RE
    Cytokine; 1998 Apr; 10(4):295-302. PubMed ID: 9617575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncostatin M induces the differentiation of breast cancer cells.
    Douglas AM; Grant SL; Goss GA; Clouston DR; Sutherland RL; Begley CG
    Int J Cancer; 1998 Jan; 75(1):64-73. PubMed ID: 9426692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divergent effects of oncostatin M on astroglioma cells: influence on cell proliferation, invasion, and expression of matrix metalloproteinases.
    Chen SH; Gillespie GY; Benveniste EN
    Glia; 2006 Jan; 53(2):191-200. PubMed ID: 16206166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective activations of STAT3 Ser727 and PKC isoforms lead to oncostatin M resistance in metastatic melanoma cells.
    Lacreusette A; Barbieux I; Nguyen JM; Pandolfino MC; Dréno B; Jacques Y; Godard A; Blanchard F
    J Pathol; 2009 Apr; 217(5):665-76. PubMed ID: 19097071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The oncostatin M signalling pathway: reversing the neoplastic phenotype?
    Grant SL; Begley CG
    Mol Med Today; 1999 Sep; 5(9):406-12. PubMed ID: 10462753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of LIF expression in human melanoma cells by oncostatin M.
    Heymann D; Blanchard F; Raher S; De Groote D; Godard A
    Immunol Lett; 1995 Jun; 46(3):245-51. PubMed ID: 7590943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tamoxifen increases cytotoxic effects of fotemustine. Experimental results on cell lines of human melanoma].
    Fischel JL; Barbé V; Berlion M; Formento P; Berrile J; Bizzari JP; Milano G
    Bull Cancer; 1994 Jul; 81(7):599-604. PubMed ID: 7742602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation.
    Mc Clay EF; Mc Clay ME; Albright KD; Jones JA; Christen RD; Alcaraz J; Howell SB
    Cancer; 1993 Sep; 72(6):1914-8. PubMed ID: 8364868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.
    Lacreusette A; Lartigue A; Nguyen JM; Barbieux I; Pandolfino MC; Paris F; Khammari A; Dréno B; Jacques Y; Blanchard F; Godard A
    J Pathol; 2008 Dec; 216(4):451-9. PubMed ID: 18798220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncostatin M enhances the expression of prostaglandin E2 and cyclooxygenase-2 in astrocytes: synergy with interleukin-1beta, tumor necrosis factor-alpha, and bacterial lipopolysaccharide.
    Repovic P; Mi K; Benveniste EN
    Glia; 2003 Jun; 42(4):433-46. PubMed ID: 12730964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? (Review).
    Toma S; Ugolini D; Palumbo R
    Int J Oncol; 1999 Aug; 15(2):321-37. PubMed ID: 10402244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice.
    Conley BA; Ramsland TS; Sentz DL; Wu S; Rosen DM; Wollman M; Eiseman JL
    Cancer Chemother Pharmacol; 1999; 43(3):183-97. PubMed ID: 9923548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.